Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Activated T-Cells Expressing Second or Third Generation CD19-Specific Chimeric Antigen Receptors for Advanced B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (SAGAN)

Next Previous
Trial Profile

Phase I Study of Activated T-Cells Expressing Second or Third Generation CD19-Specific Chimeric Antigen Receptors for Advanced B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (SAGAN)

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Biomarker
  • Acronyms SAGAN

Most Recent Events

  • 11 Jan 2021 Biomarkers information updated
  • 17 Dec 2013 Planned end date changed from 1 Oct 2031 to 1 Jan 2032 as reported by ClinicalTrials.gov.
  • 17 Dec 2013 Planned initiation date changed from 1 Oct 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top